NuVasive (NASDAQ:NUVA) Updates FY21 Earnings Guidance

NuVasive (NASDAQ:NUVA) updated its FY21 earnings guidance on Monday. The company provided earnings per share guidance of $2.25-2.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.30. The company issued revenue guidance of $1.19-1.21 billion, compared to the consensus revenue estimate of $1.20 billion.NuVasive also updated its FY 2021 guidance to $2.250-$2.350 EPS.

A number of equities research analysts have issued reports on the company. Canaccord Genuity reaffirmed a hold rating on shares of NuVasive in a research report on Tuesday, May 25th. Needham & Company LLC reaffirmed a buy rating on shares of NuVasive in a research report on Thursday, July 29th. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, NuVasive has an average rating of Hold and an average price target of $67.54.

NASDAQ:NUVA opened at $60.49 on Wednesday. The stock’s 50 day moving average price is $61.46 and its 200 day moving average price is $65.26. The company has a market capitalization of $3.13 billion, a PE ratio of 3,026.01, a P/E/G ratio of 3.08 and a beta of 1.32. The company has a quick ratio of 2.30, a current ratio of 3.95 and a debt-to-equity ratio of 1.05. NuVasive has a 52-week low of $43.11 and a 52-week high of $72.61.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Wednesday, July 28th. The medical device company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.17. The firm had revenue of $294.83 million for the quarter, compared to the consensus estimate of $286.17 million. NuVasive had a return on equity of 12.47% and a net margin of 0.16%. As a group, sell-side analysts anticipate that NuVasive will post 2.31 EPS for the current fiscal year.

In related news, CEO James Christopher Barry sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 25th. The stock was sold at an average price of $70.00, for a total transaction of $350,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.89% of the company’s stock.

NuVasive Company Profile

NuVasive, Inc engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring.

Featured Story: What is the accumulation/distribution indicator?

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with's FREE daily email newsletter.